期刊文献+

各国生物类似药适应症外推技术要求的比对研究及完善我国生物类似药适应症外推技术要求的建议 被引量:2

Comparative study on the technical requirements of extrapolation for indications of biosimilar drugs in different countries and recommendation on improvement for China
原文传递
导出
摘要 生物类似药的适应症外推,需要满足科学的前提条件。通过对美国、欧盟等国家以及WHO生物类似药适应症外推技术要求进行比对研究,提炼生物类似药适应症外推的前提条件,设计问卷、开展调研和研讨;结合对比研究、调研及专家研讨,提出完善我国生物类似药适应症外推技术要求考量的建议。 The indication extrapolation of biosimilar drugs needs to meet the preconditions of science.In this paper,a comparative study was conducted on the technical requirements for the indication extrapolation of biological similar drugs in the United States,the European Union and other countries as well as WHO,so as to extract the preconditions for the indication extrapolation of biological similar drugs.Questionnaires were designed,and investigations and discussions were conducted.Combined with the comparative study,investigation and expert discussion,some suggestions are put forward to improve the technical requirements for the extrapolation of indications for biosimilar drugs in China.
作者 吴其威 王海辉 张彦彦 马玉琴 傅道田 WU Qi-wei;WANG Hai-hui;ZHANG Yan-yan;MA Yu-qin;FU Dao-tian(Livzon Monoclonal Antibody Biotechnology Co.,Ltd,Zhuhai 519090,China;Pfizer investment Co.Ltd,Beijing 100000,China;School of Yeehong Business,Shenyang Pharmaceutical University,Beijing 100027,China)
出处 《现代药物与临床》 CAS 2019年第4期904-906,共3页 Drugs & Clinic
关键词 生物类似药 适应症外推 问卷调研 比对研究 建议 bio-similar drugs extrapolation for indications comparative study questionnaire survey recommendations
  • 相关文献

参考文献1

二级参考文献3

共引文献8

同被引文献4

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部